BiotechTube

VX-147

Phase 1Completed
0 watching 0 views this week💤 Quiet
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Focal Segmental Glomerulosclerosis (FSGS)

Conditions

Focal Segmental Glomerulosclerosis (FSGS)

Trial Timeline

Jul 19, 2023 → Sep 2, 2023

NCT ID
NCT05955872

About VX-147

VX-147 is a phase 1 stage product being developed by Vertex Pharmaceuticals for Focal Segmental Glomerulosclerosis (FSGS). The current trial status is completed. This product is registered under clinical trial identifier NCT05955872. Target conditions include Focal Segmental Glomerulosclerosis (FSGS).

Hype Score Breakdown

Clinical
10
Activity
5
Company
9
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT05955872Phase 1Completed
NCT04340362Phase 2Completed

Competing Products

20 competing products in Focal Segmental Glomerulosclerosis (FSGS)

See all competitors
ProductCompanyStageHype Score
OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved
85
DapagliflozinAstraZenecaApproved
85
Enfuvirtide + Tenofovir-EmtricitabineRochePhase 2
52
CCX140-BAmgenPhase 2
51
PF-06730512PfizerPhase 2
51
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, ZonisamidePfizerApproved
84
VX-147Vertex PharmaceuticalsPhase 2
51
IXPVertex PharmaceuticalsPhase 1
32
fresolimumab + fresolimumab + PlaceboSanofiPhase 2
51
GC1008 + GC1008 + GC1008 + GC1008SanofiPhase 1
32
frexalimab + brivekimig + rilzabrutinib + placeboSanofiPhase 2
51
VivaglobinCSLPhase 2
51
UCB0942UCBPhase 2
49
Levetiracetam + Carbamazepine + LamotrigineUCBApproved
82
Brivaracetam + BrivaracetamUCBPhase 2
49
LacosamideUCBPhase 2
49
UCB0942 + UCB0942 + PlaceboUCBPhase 2
49
LacosamideUCBPre-clinical
20
ARGX-117ArgenxPhase 2
49
Empasiprubart + IVIG (Intravenous Immunoglobulin)ArgenxPhase 3
74

Other Products from Vertex Pharmaceuticals

LUM/IVAApproved
84
suzetrigineApproved
84
SuzetrigineApproved
84
LUM/IVA + PlaceboApproved
84
SuzetrigineApproved
84